Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Key Slides
Question of the Week
Donate
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Menu
Andrea Lynn Cox, MD, PhD
Andrea Lynn Cox, MD, PhD
Professor of Medicine
The Johns Hopkins University
Baltimore, MD
CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Key Slides
Question of the Week
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Fellow Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Practice Question of the Week
January 6, 2025: Co-Infections in the Setting of Antiretroviral Therapy
A 26-year-old man originally from Brazil presents to care for an initial evaluation after being diagnosed with HIV during routine testing. He is asymptomatic, with no past medical history or prior opportunistic infections. He has a CD4+ count of 540 cells/µL and a plasma HIV RNA level of 120,000 copies/mL. Routine screening for latent tuberculosis with an interferon gamma release assay is positive, and his chest radiograph is normal. He denies any symptoms of active tuberculosis. When you explain he will need to be treated for latent tuberculosis infection, the patient expresses concern about pill burden and adherence, emphasizing the need for a simple and manageable treatment regimen. Which of the following regimens do you recommend, considering both antiretroviral therapy (ART) and latent tuberculosis infection?
A. A ritonavir-boosted protease inhibitor-based ART with daily rifapentine and isoniazid (1HP)
B. A dolutegravir (DTG) 50 mg once-daily regimen with once-weekly isoniazid and rifapentine (3HP)
C. Rifamycin-based treatment is not recommended, so daily isoniazid (9H)
D. A DTG 50 mg once-daily regimen with daily rifapentine and isoniazid (1HP)
View the On-Demand Course
View the Presentation
View Archived Questions
Leave Feedback
Subscribe
CLOSE
